An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Phase: PHASE2
Conditions: Irritable Mood, Huntington's Disease
Sponsor: Azevan Pharmaceuticals

Official Title: An Exploratory Phase II Study to Determine the 
Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor 
Antagonist (SRX246) in Irritable Subjects with Huntington's Disease 
(HD)  
NCT02507284 
Document Date:  July 28, 2016